Ellis Investment Partners LLC raised its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 67.8% during the third quarter, Holdings Channel.com reports. The fund owned 9,189 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,713 shares during the quarter. Ellis Investment Partners LLC’s holdings in Jazz Pharmaceuticals were worth $1,163,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its position in shares of Jazz Pharmaceuticals by 28.2% in the second quarter. Renaissance Technologies LLC now owns 2,555,801 shares of the specialty pharmaceutical company’s stock valued at $364,355,000 after acquiring an additional 562,700 shares during the period. Nuveen Asset Management LLC increased its position in shares of Jazz Pharmaceuticals by 4,979.1% during the second quarter. Nuveen Asset Management LLC now owns 1,924,270 shares of the specialty pharmaceutical company’s stock valued at $274,324,000 after buying an additional 1,886,384 shares during the period. Boston Partners increased its position in shares of Jazz Pharmaceuticals by 2.7% during the second quarter. Boston Partners now owns 1,341,023 shares of the specialty pharmaceutical company’s stock valued at $191,116,000 after buying an additional 35,360 shares during the period. LSV Asset Management increased its position in shares of Jazz Pharmaceuticals by 12.5% during the second quarter. LSV Asset Management now owns 1,127,120 shares of the specialty pharmaceutical company’s stock valued at $160,682,000 after buying an additional 125,470 shares during the period. Finally, AQR Capital Management LLC increased its position in shares of Jazz Pharmaceuticals by 46.9% during the second quarter. AQR Capital Management LLC now owns 1,057,019 shares of the specialty pharmaceutical company’s stock valued at $147,496,000 after buying an additional 337,396 shares during the period. Hedge funds and other institutional investors own 87.62% of the company’s stock.

A number of equities research analysts have weighed in on the stock. Zacks Investment Research cut shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating and set a $138.00 price objective on the stock. in a report on Friday, September 13th. Oppenheimer set a $176.00 price objective on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, September 26th. HC Wainwright restated a “hold” rating and issued a $147.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 8th. Piper Jaffray Companies cut shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $205.00 to $142.00 in a report on Wednesday, August 21st. Finally, Mizuho set a $148.00 price objective on shares of Jazz Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, July 3rd. Two research analysts have rated the stock with a sell rating, five have given a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $168.43.

In other news, Director Catherine A. Sohn sold 726 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $135.65, for a total value of $98,481.90. Following the transaction, the director now owns 9,574 shares in the company, valued at $1,298,713.10. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Bruce C. Cozadd sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $130.00, for a total transaction of $65,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,597 shares of company stock worth $764,057. Insiders own 4.30% of the company’s stock.

JAZZ traded up $0.33 during midday trading on Wednesday, reaching $118.91. The company’s stock had a trading volume of 384,026 shares, compared to its average volume of 555,386. The firm has a market capitalization of $6.76 billion, a price-to-earnings ratio of 9.71, a PEG ratio of 1.55 and a beta of 1.11. The company has a current ratio of 3.71, a quick ratio of 3.52 and a debt-to-equity ratio of 0.58. Jazz Pharmaceuticals PLC has a 1 year low of $113.52 and a 1 year high of $166.29. The stock’s 50-day moving average is $128.57 and its 200-day moving average is $134.05.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.16 by $0.49. The firm had revenue of $534.13 million for the quarter, compared to the consensus estimate of $507.23 million. Jazz Pharmaceuticals had a net margin of 32.99% and a return on equity of 27.72%. The business’s revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.49 earnings per share. As a group, equities research analysts forecast that Jazz Pharmaceuticals PLC will post 13.44 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Further Reading: What is the Book Value of a Share?

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.